The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy - PubMed (original) (raw)
Clinical Trial
. 2012 Oct;23(10):2605-2612.
doi: 10.1093/annonc/mds203. Epub 2012 Aug 21.
Affiliations
- PMID: 22910840
- DOI: 10.1093/annonc/mds203
Free article
Clinical Trial
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
L C Hanker et al. Ann Oncol. 2012 Oct.
Free article
Abstract
Background: Despite recent progress in the treatment of ovarian cancer, the majority of patients eventually relapse. There is little information on the effectiveness of chemotherapy in higher treatment lines.
Patients and methods: Characterization of the second to sixth line therapy and its effects on survival was carried out, based on data of n = 1620 patients from three large randomized phase III trials investigating primary therapy.
Results: Median progression-free survival (PFS) after the first, second, third, fourth and fifth relapse was 10.2 [95% confidence interval (CI) 9.6-10.7], 6.4 (5.9-7.0), 5.6 (4.8-6.2), 4.4 (3.7-4.9) and 4.1 (3.0-5.1) months, respectively. Median overall survival (OS) after the first, second, third, fourth and fifth relapse was 17.6 (95% CI 16.4-18.6), 11.3 (10.4-12.9), 8.9 (7.8-9.9), 6.2 (5.1-7.7) and 5.0 (3.8-10.4) months, respectively. The most frequent second and third line chemotherapy was platinum combination (n = 313, 24.5%) and topotecan (n = 118, 23.6%), respectively. Relapse treatment improved PFS and OS at the second to fourth recurrence, although frequently not performed according to the standard of care. In multivariate analysis, platinum sensitivity and optimal primary tumor debulking were revealed as independent prognostic factors for PFS up to third relapse.
Conclusion: A maximum of three lines of subsequent relapse treatment seems to be beneficial for patients with recurrent ovarian cancer. Optimal primary tumor debulking and platinum sensitivity remain independent prognostic factors even after more frequent relapses.
Similar articles
- Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Kyrgiou M, et al. J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63. doi: 10.1093/jnci/djj443. J Natl Cancer Inst. 2006. PMID: 17105988 - Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y. Nishio S, et al. J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1. J Cancer Res Clin Oncol. 2009. PMID: 18830625 - Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Meier W, et al. Gynecol Oncol. 2009 Aug;114(2):199-205. doi: 10.1016/j.ygyno.2009.04.026. Epub 2009 May 14. Gynecol Oncol. 2009. PMID: 19446314 Clinical Trial. - Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R. Main C, et al. Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. doi: 10.3310/hta10090. Health Technol Assess. 2006. PMID: 16545208 Review. - Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A. Colombo N, et al. Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.
Cited by
- Acetate drives ovarian cancer quiescence via ACSS2-mediated acetyl-CoA production.
Sharrow AC, Megill E, Chen AJ, Farooqi A, Tangudu NK, Uboveja A, McGonigal S, Hempel N, Snyder NW, Buckanovich RJ, Aird KM. Sharrow AC, et al. Mol Metab. 2024 Nov;89:102031. doi: 10.1016/j.molmet.2024.102031. Epub 2024 Sep 19. Mol Metab. 2024. PMID: 39304063 Free PMC article. - Development of a nomogram to predict prognosis in ovarian cancer: a SEER-based study.
Sun H, Yan L, Chen H, Zheng T, Zhang Y, Wang H. Sun H, et al. Transl Cancer Res. 2020 Oct;9(10):5829-5842. doi: 10.21037/tcr-20-1238. Transl Cancer Res. 2020. PMID: 35117197 Free PMC article. - Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations.
Hallqvist A, Bergmark K, Bäck T, Andersson H, Dahm-Kähler P, Johansson M, Lindegren S, Jensen H, Jacobsson L, Hultborn R, Palm S, Albertsson P. Hallqvist A, et al. J Nucl Med. 2019 Aug;60(8):1073-1079. doi: 10.2967/jnumed.118.220384. Epub 2019 Jan 25. J Nucl Med. 2019. PMID: 30683761 Free PMC article. - Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Lee YC, King MT, O'Connell RL, Lanceley A, Joly F, Hilpert F, Davis A, Roncolato FT, Okamoto A, Bryce J, Donnellan P, Oza AM, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Feeney A, Kaminsky MC, Diamante K, Stockler MR, Friedlander ML; GCIG Symptom Benefit Group. Lee YC, et al. Int J Gynecol Cancer. 2022 Jun 6;32(6):761-768. doi: 10.1136/ijgc-2021-003142. Int J Gynecol Cancer. 2022. PMID: 35086926 Free PMC article. - A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. Oronsky B, et al. Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25. Med Oncol. 2017. PMID: 28444622 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical